Sparsentan has toxicity warning particularly related to liver toxicity, foetal toxicity and certain drug interactions - “the company will have to run a risk evaluation and mitigation strategy, or REMS, as part of the approval. It will require doctors to go through special training, and patients to be enrolled in a monitoring program, in order for the drug to be prescribed.”
- Forums
- ASX - By Stock
- DXB Media thread.
Sparsentan has toxicity warning particularly related to liver...
Featured News
Add DXB (ASX) to my watchlist
(20min delay)
|
|||||
Last
40.0¢ |
Change
-0.010(2.44%) |
Mkt cap ! $220.2M |
Open | High | Low | Value | Volume |
41.5¢ | 42.0¢ | 39.5¢ | $839.4K | 2.070M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 35000 | 39.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
40.0¢ | 83901 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 35000 | 0.395 |
7 | 153879 | 0.390 |
8 | 193916 | 0.385 |
9 | 349785 | 0.380 |
5 | 212000 | 0.375 |
Price($) | Vol. | No. |
---|---|---|
0.400 | 33901 | 3 |
0.405 | 22128 | 1 |
0.410 | 125260 | 4 |
0.415 | 154602 | 6 |
0.420 | 119006 | 3 |
Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |